Listen to the brilliant MarleenKokLab on the ESMO - Eur. Oncology website! Lectures posted on line, great discussions and education. OncoAlert #ESMObreast24

More manuscripts being posted all the time! Great reviews and commentaries on timely topics!

@asco educational manuscripts! Find them on pubmed and on the asco website.

OncoAlert

Important analysis. Now we need to know why - and most importantly the optimal duration of adjuvant CDKi. And how much benefit for lower risk disease! Why is there liver tox in some? Predictors? OncoAlert

Agree. The Demeter trial will evaluate maintenance HP after response to first line TDXd, an important question and aimed to reduce toxicity and cost of therapy. Javier Cortes MD PhD

Eva Schumacher-Wulf @MammaMiaMagazi brings the important person-actually-taking-these-drugs perspective to the discussion of toxicities at #ESMOBreast24

*we do not have effective enough Rx for pts with early TNBC recurrence after current standard Rx - atezo doesn't add. We need to Rx more effectively in the neoadjuv setting before expansion of resistant clones & reduced host immunity. Rebecca Dent Sara Tolaney #ESMObreast24

Absolutely agree. A lot of promise. And just that. Promise. Should not be considered for Rx decisions outside of clinical trials. OncoAlert logy

Really interesting analysis by Otto Metzger and colleagues. ILC biology is different and we need to evaluate this subset separately and design focused ILC trials. Even ILC is very heterogeneous. Nice work! #ESMOBreast24 ESMO - Eur. Oncology OncoAlert

Key message. Everyone deserves fertility preservation before Rx. No impact on outcome. Very important for our patients, great work Matteo Lambertini, MD PhD #ESMOBreast24 ESMO - Eur. Oncology

Proud of @myesmo for this session and important topic! Dr. Kelly Shanahan in action with important insights and lessons for us all. #ESMOBreast24

Many congratulations for this very well deserved recognition - award ceremony at ASCO 24!

Indeed exciting lineup! Appreciate this list. Also - don't miss Capitello 291 PFS2 demonstrating continued efficacy of capi/fulv vs fulv through subsequent lines of Rx. OncoAlert ESMO - Eur. Oncology #ESMOBreast24

Join us for this great program! OncoAlert

On my way now! Looking forward to a great meeting and seeing friends and colleagues! OncoAlert

A truly remarkable and selfless woman. She lived and gave so much in just 38 years. ⁦OncoAlert⁩ Kris Hallenga obituary: Uncompromising breast cancer awareness campaigner - The Times of London apple.news/A9nRWCwF6R8KVY…

Yes another positive trial! Looking forward to data at ASCO - one big question is impact of sequential therapy. Does sequence matter? Enhertu demonstrated stat significant improvement in PFS in HR+HER2-low MBC after > or = 1 lines of ET in DB06 PhIII trial astrazeneca.com/media-centre/p…

Great new resource! OncoAlert

Well deserved Sam Brondfield, MD, MAEd - you are an amazing physician and so dedicated to world wide education! UCSF Helen Diller Family Comprehensive Cancer Ctr ASCO

Congrats to my colleagues at UCSF for their appointments to asco program committees! Well deserved!

Gripping essay from Louise Aronson nejm.org/doi/full/10.10…

You put one toe on the aggressive care escalator and off you go, powerless to stop it (my tweet length summary, read the whole essay). Shouldn't be this way. #hapc #meded #geriatrics UCSF Geriatrics